Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. 

Biotechnology

Bolt Biotherapeutics

Willie Quinn

Wesley Burwell

Sarah Nemec

Pam Howland

Nathan Ihle

Michael N. Alonso

Lynn Ferguson Lewis

Lu Xu

Grant Yonehiro

Dawn Colburn

Calvin Leung

Leadership Team

Clinical Development and Research

Laboratory Operations and Quality Control

Finance and Accounting

Teams at Bolt Biotherapeutics

Leadership Team

Clinical Development and Research

Laboratory Operations and Quality Control

Finance and Accounting